Sanofi, friends stage anti-cancer skating extravaganza

Share this article:

Sanofi-Aventis is partnering with four major cancer patient groups and Wachovia to produce a star-studded series of events aimed at raising awareness of women's cancers.

The two-year campaign debuts Oct. 14 with “Frosted Pink, presented by Sanofi-Aventis and Wachovia,” a TV special featuring celebrities like Sharon Osbourne and William Baldwin and musicians including Heart, Rascal Flatts, Kenneth “Babyface” Edmonds, Anastacia and Joss Stone along with figure skaters like Peggy Fleming, Oksana Baiul and Sasha Cohen.

The figure skating community has been hard hit by breast cancer and other women's cancers, a spokeswoman for the campaign said, and each of the show's stars has a personal connection to women's cancers.

The TV event, appearing on ESPN and ABC, is intended to drive viewers to the Web site, frostedpink.org. Organizers hope to see a community develop on the site, whose sponsors also include Merck Oncology and Bristol Myers-Squibb, along with a host of retailers, media properties and packaged goods brands.

Next year's “Pink with a twist” event will focus on gymnasts, including Shawn Johnson. The events were conceived by Edge Entertainment.

The campaign brings together an unusual constellation of patient advocacy groups, including The National Breast Cancer Coalition, The National Coalition for Cancer Survivorship, The Gynecologic Cancer Foundation and the Ovarian Cancer National Alliance.

Sanofi-Aventis products include Taxotere, indicated for breast cancer in both early and metastatic phases.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in News

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.